Age-Related Divergence of Risk-Benefit Relationship of Spironolactone Treatment for Heart Failure With Preserved Ejection Fraction.
Publication
, Journal Article
Kitzman, DW; Upadhya, B
Published in: JACC Heart Fail
December 2019
Duke Scholars
Published In
JACC Heart Fail
DOI
EISSN
2213-1787
Publication Date
December 2019
Volume
7
Issue
12
Start / End Page
1029 / 1031
Location
United States
Related Subject Headings
- Stroke Volume
- Spironolactone
- Risk Assessment
- Mineralocorticoid Receptor Antagonists
- Humans
- Heart Failure
- 3201 Cardiovascular medicine and haematology
- 1102 Cardiorespiratory Medicine and Haematology
Citation
APA
Chicago
ICMJE
MLA
NLM
Kitzman, D. W., & Upadhya, B. (2019). Age-Related Divergence of Risk-Benefit Relationship of Spironolactone Treatment for Heart Failure With Preserved Ejection Fraction. JACC Heart Fail, 7(12), 1029–1031. https://doi.org/10.1016/j.jchf.2019.09.006
Kitzman, Dalane W., and Bharathi Upadhya. “Age-Related Divergence of Risk-Benefit Relationship of Spironolactone Treatment for Heart Failure With Preserved Ejection Fraction.” JACC Heart Fail 7, no. 12 (December 2019): 1029–31. https://doi.org/10.1016/j.jchf.2019.09.006.
Kitzman DW, Upadhya B. Age-Related Divergence of Risk-Benefit Relationship of Spironolactone Treatment for Heart Failure With Preserved Ejection Fraction. JACC Heart Fail. 2019 Dec;7(12):1029–31.
Kitzman, Dalane W., and Bharathi Upadhya. “Age-Related Divergence of Risk-Benefit Relationship of Spironolactone Treatment for Heart Failure With Preserved Ejection Fraction.” JACC Heart Fail, vol. 7, no. 12, Dec. 2019, pp. 1029–31. Pubmed, doi:10.1016/j.jchf.2019.09.006.
Kitzman DW, Upadhya B. Age-Related Divergence of Risk-Benefit Relationship of Spironolactone Treatment for Heart Failure With Preserved Ejection Fraction. JACC Heart Fail. 2019 Dec;7(12):1029–1031.
Published In
JACC Heart Fail
DOI
EISSN
2213-1787
Publication Date
December 2019
Volume
7
Issue
12
Start / End Page
1029 / 1031
Location
United States
Related Subject Headings
- Stroke Volume
- Spironolactone
- Risk Assessment
- Mineralocorticoid Receptor Antagonists
- Humans
- Heart Failure
- 3201 Cardiovascular medicine and haematology
- 1102 Cardiorespiratory Medicine and Haematology